



GLPG1972

for osteoarthritis (OA)

Breakdown of joint cartilage


- 93M diagnosed patients in US, Europe & Japan
- No disease-modifying drugs approved today






'1972 protects cartilage


histopathology in mouse model




vehicle



'1972
low dose



'1972
medium dose




'1972
high dose

Source: Amantini et al OARSI 2018



Reduction of ARGs


'1972 Phase 1b trial in OA patients



Dose-dependent reduction of ARGs, well-tolerated in OA patients



ROCCELLA Phase 2b trial



- 900+ patients with knee osteoarthritis, recruited globally
- Primary endpoint: reduction in cartilage loss at 52 weeks
- Secondary: structural & clinical parameters (incl. pain & function), safety/tolerability

FDA granted fast track status
Fully recruited, topline expected H2 '20